M
Mallinckrodt
Developing, manufacturing and distributing branded and generic medicines and imaging agents
About Mallinckrodt
Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical company that has been simplifying complex medical challenges for over 150 years. The company focuses on developing, manufacturing, and distributing specialty pharmaceutical products and therapies. Mallinckrodt serves a diverse range of clients, including healthcare providers, hospitals, and patients, primarily in the United States and Europe. The company operates in the specialty pharmaceuticals market, which involves the production of drugs that treat rare and complex conditions. Mallinckrodt's business model revolves around research and development, manufacturing, and sales of its pharmaceutical products. The company generates revenue through the sale of its specialty drugs and therapies, which are often used to treat conditions such as autoimmune diseases, rare diseases, and critical care conditions. Mallinckrodt is committed to advancing environmental, social, and governance (ESG) initiatives, as highlighted in its 2022 Sustainability Report. The company's core values include being patient-centric, maintaining integrity, fostering innovation, and promoting collaboration. These values guide Mallinckrodt's efforts to improve the health and well-being of patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1867
- Headquarters
- Hazelwood, United States
- Listing
- IPO 2013
- Employees
- 2,604
- Open positions
- 53
- Dealroom signal
- 29.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 10 companies, latest Nov 2025
- Capital deployed
- $0
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2025 | $6.7B | $6.7B | Endo Pharmaceuticals Inc | ↗ |
| IPO✓Exit | Jun 2013 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mallinckrodt is 26K monthly website visits, down 44.7% over the last three months. Mallinckrodt's team declined 21.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Par HealthHazelwood, United StatesPharmaceuticals manufacturer of generics, sterile injectables, and APIs
→
Sucampo PharmaceuticalsBethesda, United StatesA public, American biopharmaceutical company focused on medical applications of a class of ion channel modulators called prostones
$1.2Bvaluation
OT
Ocera TherapeuticsPalo Alto, United StatesBiopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases
$42Mvaluation
InfaCare PharmaceuticalUpper Merion Township, United StatesEngaged in the development of pharmaceuticals for the neonatal and pediatric patient population
$48Mvaluation
Mallinckrodt Nuclear MedicineHazelwood, United StatesMallinckrodt’s Nuclear Imaging business, a longstanding diagnostic-imaging unit merged with IBA Molecular to form Curium Pharma
$690Mvaluation
Stratatech CorporationMadison, United StatesStratatech Corporation | Excellence in Regenerative Medicine
→
TherakosWest Chester, United StatesA West Chaster, Penn-based immunotherapy company
$925Mvaluation
IkariaHampton Township, United StatesDevelop and deliver innovative therapeutics and interventions to meet the significant needs of critically
$2.3Bvaluation
QP
Questcor PharmaceuticalsAnaheim, United StatesH.P. Acthar® Gel (repository corticotropin injection) 80 U/mL
→
Cadence PharmaceuticalsSan Diego, United StatesThe official site of OFIRMEV® (acetaminophen) Injection
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors5 additional known investors
Endo Pharmaceuticals Inc
ARCH Venture Partners
Signet Healthcare Partners
Sofinnova Investments
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mallinckrodt on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mallinckrodt’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.